AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Interleukin-23 subunit alpha including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Interleukin-23 subunit alpha therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Interleukin-23 subunit alpha, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Interleukin-23 subunit alpha. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Interleukin-23 subunit alpha. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Interleukin-23 subunit alpha includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Interleukin-23 subunit alpha
partner:
Reaxense
upacc:
Q9NPF7
UPID:
IL23A_HUMAN
Alternative names:
Interleukin-23 subunit p19
Alternative UPACC:
Q9NPF7; Q6NZ80; Q6NZ82; Q9H2A5
Background:
Interleukin-23 subunit alpha, also known as Interleukin-23 subunit p19, plays a pivotal role in the immune system. It forms a part of the pro-inflammatory cytokine IL-23, crucial for both innate and adaptive immunity. This protein, upon being released by antigen-presenting cells like dendritic cells or macrophages, binds to its receptor complex, activating pathways such as JAK2, TYK2, p38 MAPK, and NF-kappa-B. These pathways lead to the production of pro-inflammatory cytokines, including IL-17, and are essential for intracellular bacterial clearance and the expansion of T-helper 17 cells.
Therapeutic significance:
Understanding the role of Interleukin-23 subunit alpha could open doors to potential therapeutic strategies. Its involvement in the activation of immune responses and the production of pro-inflammatory cytokines positions it as a target for modulating immune system disorders.
